Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nidan Laboratories and Healthcare (NSE:NIDAN) Cash Conversion Cycle Explanation
Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.
Be Aware
CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.
The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.
Nidan Laboratories and Healthcare Cash Conversion Cycle Related Terms
Nidan Laboratories and Healthcare Cash Conversion Cycle Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nidan Laboratories and Healthcare Cash Conversion Cycle Chart
NSE:NIDAN vs TMO, DHR, IDXX: Cash Conversion Cycle Comparison
For the Diagnostics & Research subindustry, Nidan Laboratories and Healthcare's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nidan Laboratories and Healthcare Cash Conversion Cycle vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Nidan Laboratories and Healthcare's Cash Conversion Cycle distribution charts can be found below:
* The bar in red indicates where Nidan Laboratories and Healthcare's Cash Conversion Cycle falls into.
Nidan Laboratories and Healthcare Cash Conversion Cycle Calculation
Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.
Cash Conversion Cycle is one of several measures of management effectiveness.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Cash Conversion Cycle of -304.49 mean?
Nidan Laboratories and Healthcare (NSE:NIDAN) has a Cash Conversion Cycle of -304.49 as of Mar. 2025. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nidan Laboratories and Healthcare and its competitors.
Is Nidan Laboratories and Healthcare's Cash Conversion Cycle too high?
Nidan Laboratories and Healthcare's current Cash Conversion Cycle is -304.49. Overall, Nidan Laboratories and Healthcare has a GF Score™ of 67/100, reflecting its overall financial health beyond just this single metric.
How does Nidan Laboratories and Healthcare's Cash Conversion Cycle compare to TMO and DHR?
Nidan Laboratories and Healthcare's Cash Conversion Cycle of -304.49 can be compared against companies in the Medical Diagnostics & Research industry. The industry median Cash Conversion Cycle is 74.74. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Conversion Cycle for a Medical Diagnostics & Research company?
The median Cash Conversion Cycle among Medical Diagnostics & Research companies is 74.74, based on 203 companies in the industry. Companies in the top quartile (top 25%) have a Cash Conversion Cycle significantly above this median, while those in the bottom quartile fall well below. However, Cash Conversion Cycle should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Conversion Cycle mean?
A high Cash Conversion Cycle can signal that a stock is expensive relative to its fundamentals. Cash conversion cycle equals sum of days inventory and days sales outstanding less days payable. View historical data on Nidan Laboratories and Healthcare and its competitors. For the Medical Diagnostics & Research industry, the median Cash Conversion Cycle is 74.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nidan Laboratories and Healthcare's current Cash Conversion Cycle is -304.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nidan Laboratories and Healthcare stock overvalued right now?
Nidan Laboratories and Healthcare (NSE:NIDAN) has a current Cash Conversion Cycle of -304.49. The current Cash Conversion Cycle is -304.49. Nidan Laboratories and Healthcare's overall GF Score™ is 67/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Conversion Cycle calculated?
Cash Conversion Cycle is calculated from a company's financial statements. For Nidan Laboratories and Healthcare (NSE:NIDAN), the current Cash Conversion Cycle is -304.49 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Nidan Laboratories and Healthcare Business Description
Nidan Laboratories and Healthcare Ltd offer diagnostic services including radiology, neurology, cardiology, dental as well as pathology services. The company provides pathology tests ranging from basic biochemistry and clinical pathology to cytogenetic and high-end molecular diagnostic tests, and radiology tests ranging from basic echocardiograms, X-Rays, and ultrasounds to radiology tests including computerized tomography scans, magnetic resonance imaging scans.
67GF Score
Get the complete analysis for NSE:NIDAN
Cash Conversion Cycle is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NIDAN has been successfully added to your 
